Potential of telmisartan in the treatment of benign prostatic hyperplasia-Reference-Cited by-同舟云学术

Potential of telmisartan in the treatment of benign prostatic hyperplasia

Published:2017-08-16 Issue: Volume: Page:
ISSN:0767-3981
Container-title:Fundamental & Clinical Pharmacology
language:en
Short-container-title:Fundam Clin Pharmacol

Author:

Ishola Ismail Ogunbayode¹^ORCID,Anunobi Charles C.²,Tijani Kehinde Habeeb³,Afolayan Olasunmbo⁴,Udokwu Victoria U.¹

Affiliation:

1. Department of Pharmacology, Therapeutics and Toxicology; Faculty of Basic Medical Sciences; College of Medicine; University of Lagos; Lagos Nigeria

2. Department of Anatomic and Molecular Pathology; Faculty of Basic Medical Sciences; College of Medicine; University of Lagos; Lagos Nigeria

3. Department of Surgery; Urology Unit; Faculty of Clinical Sciences; College of Medicine; University of Lagos; Lagos Nigeria

4. Department of Anatomy; Faculty of Basic Medical Sciences; College of Medicine; University of Lagos; Lagos Nigeria

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/fcp.12304/fullpdf

Reference36 articles.

1. Benign prostatic hyperplasia: from bench to clinic;Yoo;Korean J. Urol.,2012

2. Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management;Barkin;Can. J. Urol.,2011

3. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH);Roehrborn;Med. Clin. North Am.,2011

4. A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia;Alonso-Magdalena;Proc. Natl Acad. Sci.,2009

5. Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease;Silver;J. Urol.,1994

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging drugs for the treatment of benign prostatic hyperplasia: a 2023 update;Expert Opinion on Emerging Drugs;2024-06-14

2. Insights into the associative role of hypertension and angiotensin II receptor in lower urinary tract dysfunction;Hypertension Research;2024-02-14

3. The angiotensin converting enzyme inhibitor captopril attenuates testosterone-induced benign prostatic hyperplasia in rats; a mechanistic approach;European Journal of Pharmacology;2019-12

4. Role of PPAR-α agonist fenofibrate in the treatment of induced benign prostatic hyperplasia with dysplastic changes in rats;Fundamental & Clinical Pharmacology;2018-06-28